Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo
Stada To Commercialize In EU
Executive Summary
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.
You may also be interested in...
Calliditas Confident Of Keeping Ahead Of Travere In IgAN
The Swedish group’s Tarpeyo is reaping the benefits of an expanded US sales force and the company is confident of a big revenue rise in 2023, regardless of new competition in the IgAN field from Travere’s Filspari.
Calliditas Spies Chinese Market As Tarpeyo Continues Upwards Sales Curve
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field
Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.